Abstract:Background/Objectives: HMG-CoA reductase is an enzyme that regulates the initial stage of cholesterol synthesis, and its inhibitors are widely used in the treatment of cardiovascular diseases. Methods: We have created a set of quantitative structure-activity relationship (QSAR) models for human HMG-CoA reductase inhibitors using nested cross-validation as the primary validation method. To develop the QSAR models, we employed various machine learning regression algorithms, feature selection methods, and fingerprints or descriptor datasets. Results: We built and evaluated a total of 300 models, selecting 21 that demonstrated good performance (coefficient of determination, R2 ≥ 0.70 or concordance correlation coefficient, CCC ≥ 0.85). Six of these top-performing models met both performance criteria and were used to construct five ensemble models. We identified the descriptors most important in explaining HMG-CoA inhibition for each of the six best-performing models. We used the top models to search through over 220,000 chemical compounds from a large database (ZINC 15) for potential new inhibitors. Only a small fraction (237 out of approximately 220,000 compounds) had reliable predictions with mean pIC50 values ≥ 8 (IC50 values ≤ 10 nM). Our svm-based ensemble model predicted IC50 values < 10 nM for roughly 0.08% of the screened compounds. We have also illustrated the potential applications of these QSAR models in understanding the cholesterol-lowering activities of herbal extracts, such as those reported for an extract prepared from the Iris × germanica rhizome. Conclusions: Our QSAR models can accurately predict human HMG-CoA reductase inhibitors, having the potential to accelerate the discovery of novel cholesterol-lowering agents and may also be applied to understand the mechanisms underlying the reported cholesterol-lowering activities of herbal extracts.

Qsar Studies of Hept Derivatives As Anti-Hiv Drugs Using the Rasms Method

QSAR Research of Novel Tetrandrine Derivatives Against Human Hepatocellular Carcinoma.

Quantitative Structure Activity Relationship Models For The Prediction Of Rat Lethal Dose 50% Of Aldehydes Based On Heuristic Method And Support Vector Machine

Structure-based Rational Quest for Potential Novel Inhibitors of Human HMG-CoA Reductase by Combining CoMFA 3D QSAR Modeling and Virtual Screening.

QSAR Studies on 1-Aryl-tetrahydroisoquinoline Analogs As Active Anti-HIV Agents Based on PSO-v-SVM

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

QSAR Study of Carboxylic Acid Derivatives As HIV-1 Integrase Inhibitors

Predicting Anti‐HIV‐1 Activities of HEPT‐analog Compounds by Using Support Vector Classification

Multi-target QSAR study in the analysis and design of HIV-1 inhibitors

Three dimensional quantitative structure-activity relationship of DATA analogues as HIV-1 reverse transcriptase inhibitors

QSAR study of thiocarbamates as non-nucleoside HIV-1 reverse transcriptase in hibitors

Prediction of the Aquatic Toxicity of Aromatic Compounds to Tetrahymena Pyriformis Through Support Vector Regression

Applications of Genetic Algorithms on the Structure–activity Correlation Study of a Group of Non-Nucleoside HIV-1 Inhibitors

Quantitative Structure-Activity Relationships of Hiv-1 Integrase Inhibitors of Dkas

QSRR Modeling of Lipophilicity of New Spirohydantoin Derivatives Determined with Various TLC Systems

QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition

Docking and field-based QSAR studies of S-DABOs as HIV-1 reverse transcriptase inhibitors

Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening

Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors Ⅱ 3D-QSAR Study on 6-(1-naphthylmethyl)substituted Thymines

A Linear and Nonlinear QSAR Analysis of Benzimidazole Derivative XY123 in Prostate Cancer Treatment

The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors